

OVERCOMING INSTITUTIONAL BARRIERS TO INTEGRATED CARE: LINKAGE TO HEPATITIS C TREATMENT IN THE OPIOID AGONIST TREATMENT SETTING

Coupland H^{1,2}, Pritchard-Jones J³, Haber P^{1,2}, George J⁴ & McCaughan G³.

¹ Drug Health Services, Royal Prince Alfred Hospital, Sydney Local Health District, Australia

² Discipline of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney, Australia

³ AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney Local Health District, Australia

⁴ Storr Liver Centre, Westmead Institute for Medical Research, Department of Gastroenterology and Hepatology, Westmead Hospital and University of Sydney, Australia

Dr Heidi Coupland

Drug Health Services, Royal Prince Alfred Hospital

King George V Building,

Missenden Rd,

Camperdown NSW 2050

P: (02) 9515 6419

E: Heidi.Coupland@health.nsw.gov.au

Background: Increasing uptake of direct-acting antiviral (DAA) treatment by people who inject drugs (PWID) with chronic hepatitis C virus (HCV) infection is crucial for reaching global elimination targets by 2030. Integration of hepatitis C and opioid agonist treatment (OAT) services has the potential to facilitate linkage of PWID to HCV treatment and care. This presentation explores institutional factors impacting on treatment uptake in hospital-based OAT settings and highlights effective strategies for facilitating access to treatment for clients. In 2016-7 the clinics had rolled out DAA and 83 clients were treated.

Methods: Thirty in-depth interview were conducted with clients (n=13) and staff (n=17) from two hospital-based OAT clinics in Sydney, Australia. Interview data were thematically analysed using constant comparative methods.

Results: Factors influencing HCV treatment initiation for clients included a focus on other priorities, other health problems requiring investigation, concerns about side effects, and the inconvenience of additional appointments to access testing and treatment, and with filling scripts. OAT clinic staff reported that lack of resources and limitations in staff capacity to perform venepuncture and prescribe HCV treatment resulted in referrals to other staff and services. Prescribing-related policies, dispensing fees, and the need to order in medications at some community pharmacies raised the number of client visits required to initiate treatment. A range of approaches were adopted to address barriers including training clinic staff in venepuncture, escorting clients to services for testing, involvement of a peer worker, changing prescribing practices, covering the cost of dispensing fees for clients, shared care arrangements, and providing additional follow-up and monitoring of clients seeking treatment.

Conclusion: Challenges exist in integrating HCV treatment into hospital-based OAT where resources are often limited. Models of care need to include a range of intervention options to accommodate the diverse support needs of clients with complex health and social problems.

Disclosure of Interest Statement

Professor McCaughan has received funding from a Medical Research Future Fund grant related to this project. No pharmaceutical grants were received in the development of this study.

Professor Haber has received funding from Gilead, Abbvie and Indivior for consultation fees on advisory boards and from Camurus for research involving opioid agonist treatment. No pharmaceutical grants were received in the development of this study.

Nil disclosures for Professor Jacob George, Janice-Pritchard-Jones or Dr Heidi Coupland.